Carbogen Amcis has entered a collaboration with UK-based ADC Biotechnology to provide development and manufacturing services for antibody drug conjugates (ADCs), a key anti-cancer treatment platform. ADC Bio is developing a “lock and release” solid phase immobilization technology for efficient production of ADCs.
 
The alliance will offer a complete range of services for the development, scale-up, manufacturing and formulation of protein-based drug conjugates. ADC Bio will provide access to solid phase immobilization technologies for conjugation and long-term storage of ADCs, and Carbogen will focus on small- to large-scale GMP supply and formulation of ADCs.
 
“Carbogen Amcis’ goal is to help clients to advance drug candidates through the development pipeline with greater speed by delivering innovative chemistry solutions,” said Mark Griffiths, chief executive officer of Carbogen Amcis. “Through this alliance, we provide our customers access to ADC Bio’s particular expertise in the conjugation of proteins and antibodies to toxins by ‘lock and release’ technology. The partnership will enable us to provide robust and efficient processes under GMP at multiple scales, which presents a significant new service offering for ADC developers and producers.”